Los mejores podcasts de Aya Cancer (2024)

1
Prolonging remission in AML: current approaches & future outlooks 31:27

4d ago31:27

31:27

Today's podcast features a discussion with leading experts Harry Erba, MD, PhD, Duke University, Durham, NC, Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, on strategies to prolong remission in acute myeloid leukemia (AML). They focu…

1
{Research Round-Up) More Gains, Less Load? It's Possible with THIS 1:05:58

4d ago1:05:58

1:05:58

Send us a text Blood Flow Restriction (BFR) training has been used for years to help patients make greater gains during strength training. But does BFR belong in oncology rehab? Short answer: yes! Dr. Kelly Martin, PT, is back on the podcast to discuss the benefits of BFR, plus important safety considerations for our oncology patients. Dr. Martin a…

1
One Woman's Fight for a Future Beyond MBC with Guest Speaker - Tami Eagle Bowling! 40:46

11d ago40:46

40:46

Join Living Our Breast Lives founder, Wren, and special guest, Tami Eagle Bowling, the creator of LightUpMBC Live, for this powerful and uplifting episode as they discuss Tami's continued efforts for funding Metastatic Breast Cancer research, helping to create a better future for all diagnosed! With no family history, at the age of 41, Tami Eagle B…

1
A focus on the use of artificial intelligence to personalize blood cancer care 28:55

12d ago28:55

28:55

Welcome to the final episode of VJHemOnc's Blood Cancer Awareness Month special series! This episode focuses on the role of artificial intelligence (AI) in personalizing blood cancer care. Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses the value of AI in hematological oncology and how it is currently used i…

1
A Postdoc’s Perspective: Dr. Aya Kamzina’s Path to Research 15:35

15d ago15:35

15:35

Every September, the scientific community recognizes postdoctoral researchers during Postdoc Appreciation Week. Postdocs bring new ideas and deep expertise as they tackle complex questions and expand knowledge through experiments. In this month’s episode of TGen Talks, Aya Kamzina, Ph.D., one of TGen’s 11 postdoctoral researchers, shares her journe…

1
A focus on pediatric leukemias: trials, treatments, & challenges 17:44

17d ago17:44

17:44

Welcome to the third episode of VJHemOnc’s Blood Cancer Awareness Month special series! The focus of this episode is pediatric acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). You will hear from Michele Redell, MD, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX, who shares insights into the Pediatric Acu…

1
Proven Tips & Tools To Survive Your Oncology Specialty Certification Prep 50:39

22d ago50:39

50:39

Send us a text Oncology specialization can feel like Fight Club - because nooooobody talks about it until you’re in it. So in this episode we’re busting open the doors & diving into the process of specialization with Dr. Tori Crook. Dr. Crook is a board certified clinical specialist in oncologic physical therapy & acute care oncology physical thera…

1
A focus on the psychosocial impacts of living with blood cancer 36:22

24d ago36:22

36:22

Welcome to the second episode of VJHemOnc’s Blood Cancer Awareness Month special series! Today's episode focuses on the psychosocial impacts of living with blood cancer. First, you will hear from Lorna Warwick, BA, Lymphoma Coalition, Toronto, Canada, who shares the work of the Lymphoma Coalition Global Patient Survey. Next, you will hear insights …

1
Finish Line Focus: Completing Your Oncology Case Report on Time 37:29

1M ago37:29

37:29

Send us a text With just a few weeks left until the September 30 deadline, it's officially crunch time for your ABPTS Oncology Case Report and Application! In this episode, we're going to break down how to strategically approach your writing and how to avoid the common pitfalls that can derail your progress. Plus, I’ll share some tips on budgeting …

1
Global perspectives on blood cancers: addressing disparities in awareness, diagnosis, and treatment 18:54

1M ago18:54

18:54

Welcome to the first episode of VJHemOnc's Blood Cancer Awareness Month special series! This episode focuses on global perspectives of blood cancers and addresses the disparities that exist in awareness, diagnosis, and treatment. First, Lalit Kumar, MD, MBBS, Artemis Hospital, New Delhi, India, discusses challenges that exist in the management of b…

1
Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more 11:50

1M ago11:50

11:50

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPNs) characterized by the overproduction of red blood cells and platelets, respectively, due to mutations in hematopoietic stem cells. In this podcast, experts Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL; Lucia Masarova, MD, The University of Te…

1
Episode 74: Breaking Down Multiple Myeloma’s New Subtypes and Their Impact 16:15

2M ago16:15

16:15

Scientists at TGen have released the results of a more than decade-long study into multiple myeloma. Looking at more than 1100 patients from four different countries, scientists identified new genetic subtypes of the disease, providing insights that could transform how we approach treatment (see related story above).Listen as Jonathan Keats, Ph.D.,…

1
Beating the Odds as a 5 YEAR MTNBC THRIVER 45:37

2M ago45:37

45:37

Join Living Our Breast Lives founder, Wren, for this fierce solo episode as she delves into the significance of her 5 YEAR MBC Anniversary as a 35 year old mTNBC Thriver! Hear her compelling diagnosis story and engage in an empowering conversation about advocacy and the critical importance of continued funding for Metastatic Breast Cancer research!…

1
10 Years of Prospective Surveillance Model: Why Aren't We Further Along? (Replay) 1:23:35

2M ago1:23:35

1:23:35

Send us a text It's been 12 years since the Prospective Surveillance Model was first published. This model saves our patients money, can prevent functional decline, & has changed our entire paradigm of how we treat people with cancer. So why is it still so rare to see it implemented? Buckle up, OncoPT, because there’s a lot to cover today. But it’s…

1
Hemophilia updates from ISTH 2024: ongoing clinical trials, emerging gene therapies & remaining challenges 18:41

2M ago18:41

18:41

This week's VJHemOnc podcast brings you updates in hemophilia from the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Bangkok, Thailand, and virtually. You hear from experts Omolade Awodu, MBChB, MD, FMCPath, University of Benin, Benin City, Nigeria, who discusses key hemophilia clinical trials in 2024, Rad…

1
Do These Things to Treat Your Patient with Bone Metastases Better (Replay) 38:18

2M ago38:18

38:18

Send us a text If you ask any rehab professional what scares them the most about oncology patients, their answer 99.9% of the time will be bone metastases. And this fear is keeping rehab professionals from actually helping their patients with cancer (even those without bone mets). The fact is patients with bone metastases benefit from rehab, from e…

1
Inflammation and immune interventions in MDS: targeting STAT, IRAK4, & more 17:29

2M ago17:29

17:29

In myelodysplastic syndromes (MDS), chronic inflammation driven by the innate immune system plays a key role in disease progression. Signal Transducer and Activator of Transcription (STAT) and Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) are critical mediators in this process, where dysregulated signaling leads to aberrant hematopoiesis and t…

1
Collaboration Catapults Your Patient Care - Here's How To Start 39:19

2M ago39:19

39:19

Send us a text ICYMI: Katie Ledecky is 🐐 And while she’s been crushing it at #Paris2024, she’s also been serving up some lessons that cancer rehab NEEDS TO LEARN. In short, you can’t practice in a silo & realistically expect to see improved patient care. What you need instead is COMMUNITY. Learn how sharing knowledge, providing support, leading by …

1
Updates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needs 11:58

2M ago11:58

11:58

Today’s VJHemOnc podcast features experts Rabi Hanna, MD, The Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Subarna Chakravorty, MBBS, MRCPCH, FRCPath, PhD, King’s College Hospital NHS Foundation Trust, London, UK, and Ali Taher, MD, PhD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon. They discuss key updates in si…

1
{Research Round-Up} Leveraging Social Media to Improve Access for AYA Survivors 49:49

2M ago49:49

49:49

Send us a text In this first edition of our special Research Round-Up series, we dive into groundbreaking research that examines a novel way to put adolescent & young adult (AYA) survivors BACK in the driver’s seat of their care. Dr. Kelly Martin, physical therapist & TheOncoPT team member, joins Elise to discuss the importance of education and bri…

1
Episode 73: The Science of Longevity 24:52

2M ago24:52

24:52

Aging. It’s something we’d all like to do better. Americans spend an estimated $5 Billion on anti-aging products every year. But at TGen and City of Hope, scientists like TGen distinguished professor Nicholas Schork, Ph.D., are working to unlock the secrets to not just better ‘aging,’ but disease prevention alongside longevity, and are making promi…

1
Unmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trials 16:00

2M ago16:00

16:00

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by bone marrow fibrosis, extramedullary hematopoiesis, and splenomegaly, often resulting in anemia and thrombocytopenia. There are many unmet treatment needs that remain in this space. This week’s podcast features a discussion from the International Workshop on Myelodys…

1
What You Need to SHINE In OncoPT 20:11

3M ago20:11

20:11

Send us a text Oncology physical therapy is a SIGNIFICANT departure from what most people know & expect from physical therapy. Think about it: cancer itself is a red flag condition you likely learned about & how you should refer the patient with cancer back to their referring provider. And that is totally antithetical to how you as an OncoPT approa…

1
The role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024 12:13

3M ago12:13

12:13

The introduction of Bruton's tyrosine kinase (BTK) inhibitors into the treatment landscape for mantle cell lymphoma (MCL) has transformed the field and provided patients with a promising therapeutic option. In this podcast, you will hear from leading experts who discuss the value of these agents in MCL, sharing updates from EHA 2024. Tune in as Man…

1
Walnut Colon: If I Did It 58:04

3M ago58:04

58:04

Ding dong, The Juice is (still) dead! Of cancer! But speaking of juice: how do steroids work? Afterschool specials didn’t prepare us for this. A letter asks how to find a cancer bestie when you’re a queer 40-something cancer person. Have we mentioned lately that we have a Facebook group? If you need a pal, we have some excellent candidates. Is an o…

1
Novel developments in lower-risk MDS & important practical considerations when treating patients 51:42

3M ago51:42

51:42

In today’s VJHemOnc podcast, we will be sharing novel developments in lower-risk myelodysplastic syndromes (LR-MDS) and important practical considerations when treating patients. You will hear from experts Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook …

1
How to start treating your pregnant oncology patient 41:56

3M ago41:56

41:56

Send us a text In PT school, you may have heard that cancer is a disease of the old. But this is only half true. Cancer affects people of all ages, including those in their childbearing years, even during pregnancy. And you’re likely going to be seeing more of these patients in your own practice. Dr. Rebeca Segraves, PT, & Dr. Alexandra Hill, PT, a…

1
Updates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024 16:18

3M ago16:18

16:18

BCMA-targeting bispecific antibodies treat multiple myeloma by binding to BCMA on malignant plasma cells and directing T-cells to initiate targeted cell killing. This podcast provides updates on the use of BCMA-targeting bispecific antibodies in relapsed/refractory (R/R) multiple myeloma from the 2024 American Society of Clinical Oncology (ASCO) Me…

1
Charlene 49:05

3M ago49:05

49:05

Scans abound in Cancerland. What’s up with Stef? (Is a question many ask unrelated to cancer, but this time it’s relevant!) Then, is Diet Coke the new menthol cigarette? Let’s ask Amy’s nurse. That blasted jerk Glioblastoma has a new foe, as does melanoma. How do we know? Three little birds told us! In Letters, a listener asks what’s up with Olivia…

1
Adolescent and Young Adult Cancer Research and Survivorship: Helaina's Story 23:21

3M ago23:21

23:21

Dr. David Dickens from the University of Iowa talks with Helaina Hillyard, an adolescent and young adult (AYA) cancer survivor, about her experiences. Listen in as Helaina shares her journey, discussing the unique challenges of facing cancer as a young adult. Tune in for an insightful and heartfelt conversation about hope, resilience, and the reali…

1
Why It Doesn't Get Better with Time for Prostate Cancer Survivors 49:53

3M ago49:53

49:53

Send us a text Need the essentials for evaluating & treating your next patient with prostate cancer? Then you’ve come to the right place. In this interview with Dr. Matthew Johnston, PT, you’ll learn the essentials of educating, setting expectations, & prescribing interventions for prostate cancer survivors. You’ll also learn about the challenges o…

1
Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more 12:10

3M ago12:10

12:10

In today's VJHemOnc podcast, we will be sharing key updates in the treatment of chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT) from the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain. You will hear from experts Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospit…

1
Episode 72: Fowl Play: Viewing the New Strain of Bird Flu Through a Genomic Lens 19:17

4M ago19:17

19:17

On this month’s TGen Talks, David Engelthaler, Ph.D., professor and director of TGen’s Pathogen and Microbiome Division, discusses the recent surge of bird flu, also known as H5N1.H5N1 has been in the news a lot lately, but what does it all mean? Engelthaler breaks down the science and talks about the effects this particular strain might have on hu…

1
Resilience and Growth: Thriving Beyond Your ABPTS Exam Results 46:47

4M ago46:47

46:47

Send us a text If you’re listening to this in real time, we are just days away from finding out the results of the 2024 ABPTS Oncology Specialty Certification exam. It can be so easy to hinge your future as an OncoPT on finding out these results. But your worth has absolutely nothing to do with this exam. Your value as an OncoPT isn’t tied to a cer…

1
Highlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCT 8:43

4M ago8:43

8:43

Welcome to today's VJHemOnc podcast episode, where we will be sharing key highlights from the 2024 International Symposium on Amyloidosis (ISA), which was held in Rochester, MN. This podcast covers a variety of unmet needs in light chain (AL) amyloidosis, as well as emerging trials in the field. Join leading experts Mario Nuvolone, MD, PhD, Univers…

1
Six Months In: How to Stay on Track and Finish Strong in 2024 48:10

4M ago48:10

48:10

Send us a text We are halfway through 2024: let’s check in. How are YOU (like for real)? How are things going? Where are you at, compared to where you want to be? No matter what your answers are, you're in the right place right now. In today's episode, we're diving into reflecting on your 2024 progress so far, how to reassess your goals & prioritie…

1
Motivate & Move: Innovative HEP Ideas for Your Oncology Patients 46:48

4M ago46:48

46:48

Send us a text Keeping home exercise programs (HEPs) fresh and exciting is key to maintaining patient motivation & adherence. BUT it’s easy for the HEP to take a back seat to all the other stuff you have to manage in patient care. That’s why we’re spicing up the HEP in this episode, with unique exercise & physical activity ideas. To inject some lif…

1
Treating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooks 46:31

4M ago46:31

46:31

While there have been advances in the treatment of lower-risk myelodysplastic syndromes (LR-MDS) in recent years, one major challenge that remains is the treatment of patients following the failure of erythropoiesis-stimulating agents (ESAs). In this podcast, experts Amer Zeidan, MBBS, Yale Cancer Center, New Haven, CT, Valeria Santini, MD, Univers…

1
A Boundless Love for Life with AYA Thriver - Brittney Beadle! 58:40

4M ago58:40

58:40

Diagnosed at only eighteen years old, join Living Our Breast Lives founder, Wren, for this special episode with AYA Thriver, Brittney Beadle, as they dive deep into her incredible journey of advocacy as a Metastatic Breast Cancer Thriver! After countless run-ins with progression during her nine years living with MBC, Brittney remains a beacon of po…

1
DIVE IN! How going through the motions hurts your OncoPT growth 35:32

4M ago35:32

35:32

Send us a text Summer is here, which means it’s time to DIVE IN! Just like the water might be cold when you first get in, it’s crucial to embrace the discomfort & challenges that come with cancer rehab if you’re ever going to get better at treating oncology patients. So are you going to just dip your toes in? Or are you going all in on yourself & f…

1
BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients 34:39

4M ago34:39

34:39

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy originating from plasmacytoid dendritic cells, characterized by skin lesions and frequent involvement of bone marrow and lymphoid tissues. Patients have a poor prognosis, making early diagnosis and advanced treatments, including targeted therapies, crucial …

1
Episode 71: Understanding Your Risk with a PRS 20:54

5M ago20:54

20:54

This month, TGen Talks explores polygenic risk scores with Dr. David Duggan, an associate professor in the Quantitative Medicine and Systems Biology Division at TGen. A polygenic risk score is a number that indicates the combined effect of many genetic variants on a person's risk of developing a certain trait or disease. Each genetic variant adds a…

1
LISTEN TO THIS When You Have a Patient with BPPV 1:02:42

5M ago1:02:42

1:02:42

Send us a text BPPV (Benign Paroxysmal Positional Vertigo) is a common vestibular issue that affects people of all ages. BUT DID YOU KNOW there is significant crossover between BPPV and oncology? Yep - cancer treatments & even certain conditions we see in cancer rehab can increase your patient’s likelihood of developing BPPV. In this conversation, …

1
What it Actually Takes to Specialize in Cancer Rehab 56:25

5M ago56:25

56:25

Send us a text OncoPT is not always the first career path for physical therapists - today’s guest included! From starting her career at the USDA to now pioneering cancer rehab in her area, Dr. Alyssa Carey, PT, shares her journey to specializing in OncoPT, plus the major decisions that transformed her career into what it is today. Listen for all th…

1
The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies 12:34

5M ago12:34

12:34

Immunotherapeutic approaches, including CAR T-cells and bispecific antibodies, have become well-established in later lines of non-Hodgkin lymphoma (NHL) treatment. CAR T-cells are engineered to target specific antigens expressed on lymphoma cells, and bispecific antibodies simultaneously bind to both tumor cells and immune cells, enhancing the immu…

1
iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials 27:24

5M ago27:24

27:24

The 17th International Workshop on Multiple Myeloma (iwMyeloma 2024) was held recently in Miami, FL, and brought together experts from around the world to discuss the latest updates, challenges, and research in the field. In this episode, Ola Landgren, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Suzanne Lentzsch, MD, …

1
Prostate Cancer Rehab & the Soft Skills You Need to Implement 1:00:24

5M ago1:00:24

1:00:24

Send us a text Prostate cancer survivors sometimes fall into the gap between pelvic floor PT & OncoPT - who should be treating the patient & when? The short answer is all hands on deck, but Dr. Matthew Johnston, PT, breaks down exactly how to prioritize your patient’s impairments & which team your patient should see first. In today’s episode, we di…

1
Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs 11:43

5M ago11:43

11:43

Myelofibrosis (MF) is a hematologic malignancy that causes progressive bone marrow fibrosis and presents with other clinical manifestations, including anemia and splenomegaly. MF-related anemia can be challenging to manage, and strategies are being explored to improve outcomes for patients. Today's VJHemOnc podcast features experts Mary Frances McM…

1
Episode 70: United Against Brain Cancer 15:35

6M ago15:35

15:35

Glioblastoma. It’s the most aggressive and least treatable type of brain cancer. Research into treatment has been slow, mostly because of the difficulty in accessing and treating a tumor that exists behind the blood-brain barrier. A new two year fellowship into Glioblastoma Multiforme, or GBM, aims to better drug therapies to fight the cancer while…

1
Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome 22:50

6M ago22:50

22:50

Graft-versus-host disease (GvHD) is a common complication following allogeneic stem cell transplantation (alloSCT), which is typically classified as acute or chronic. In this week's VJHemOnc podcast, we'll be sharing key highlights from the 50th Annual Meeting of the EBMT, drawing focus on the biology and treatment of GvHD. Tune in as experts Moham…

Podcasts que vale la pena escuchar

Podcasts de Aya Cancer

Podcasts que vale la pena escuchar

Guia de referencia rapida